JESÚS
RUIZ CONTRERAS
Ikertzailea 2022-(e)ra arte
Hospital Clínico San Carlos de Madrid
Madrid, EspañaHospital Clínico San Carlos de Madrid -ko ikertzaileekin lankidetzan egindako argitalpenak (12)
2022
-
Clinical characteristics, health care resource utilization and direct medical costs of Rotavirus hospitalizations in Spain (2013–2018)
Human Vaccines and Immunotherapeutics, Vol. 18, Núm. 5
2021
-
Rotavirus gastroenteritis hospitalizations in provinces with different vaccination coverage rates in Spain, 2013–2018
BMC Infectious Diseases, Vol. 21, Núm. 1
2019
-
Clinical practice update of antifungal prophylaxis in immunocompromised children
Revista Espanola de Quimioterapia, Vol. 32, Núm. 5, pp. 410-425
2013
-
Expansion of serotype coverage in the universal pediatric vaccination calendar: Short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain
Clinical and Vaccine Immunology, Vol. 20, Núm. 10, pp. 1524-1530
-
Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011
Pediatric Infectious Disease Journal
2012
-
Five-year antibody persistence and safety following a booster dose of combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine
Pediatric Infectious Disease Journal, Vol. 31, Núm. 10, pp. 1074-1077
2011
-
Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: A 2-year (2007-2009) laboratory-based surveillance in Madrid
Vaccine, Vol. 29, Núm. 9, pp. 1770-1776
-
Laboratory-based, 2-year surveillance of pediatric parapneumonic pneumococcal empyema following heptavalent pneumococcal conjugate vaccine universal vaccination in madrid
Pediatric Infectious Disease Journal, Vol. 30, Núm. 6, pp. 471-474
-
Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar
Clinical and Vaccine Immunology, Vol. 18, Núm. 1, pp. 89-94
2008
-
Immunogenicity and reactogenicity of a booster dose of a novel combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age
Pediatric Infectious Disease Journal, Vol. 27, Núm. 7, pp. 579-588
2007
-
Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months
Pediatric Infectious Disease Journal, Vol. 26, Núm. 1, pp. 1-7
2006
-
Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine
Pediatric Infectious Disease Journal, Vol. 25, Núm. 8, pp. 713-720